Guocheng Huang1,2, Xinji Li1,2, Zebo Chen1, Jingyao Wang1, Chunduo Zhang1, Xuan Chen1,2, Xiqi Peng1,2, Kaihao Liu1,3, Liwen Zhao1,3, Yongqing Lai4,5, Liangchao Ni6,7. 1. Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Peking University Shenzhen Hospital, Guangdong, 518036, Shenzhen, People's Republic of China. 2. Shantou University Medical College, Shantou, Guangdong, 515041, China. 3. Anhui Medical University, Hefei, Anhui, 230032, China. 4. Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Peking University Shenzhen Hospital, Guangdong, 518036, Shenzhen, People's Republic of China. yqlord@163.com. 5. Shantou University Medical College, Shantou, Guangdong, 515041, China. yqlord@163.com. 6. Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Peking University Shenzhen Hospital, Guangdong, 518036, Shenzhen, People's Republic of China. lncord@163.com. 7. Shantou University Medical College, Shantou, Guangdong, 515041, China. lncord@163.com.
Abstract
PURPOSE: Renal cell carcinoma (RCC) accounts for about 120,000 death each year. Although surgery is a routine treatment, RCC could be fatal if not diagnosed at an early stage. This study aims to search for suitable serum biomarkers and construct a miRNA panel with high diagnostic sensitivity or specificity. METHODS: Totally 146 RCC patients and 150 normal control were involved in this three-stage study. Serum expression levels of 30 miRNAs selected from literature were tested by reverse transcription quantitative PCR (RT-qPCR) in the screening stage, the testing stage, and the validation stage. The diagnostic efficiency of miRNAs was evaluated by receiver operating characteristic (ROC) curve and area under curve (AUC) analysis. A panel with the highest diagnostic efficiency was constructed by backward stepwise logistic regression analysis. Additionally, bioinformatics analysis was used to investigate potential biological functions and mechanisms of candidate miRNAs. RESULTS: MiR-224-5p, miR-34b-3p, miR-129-2-3p and miR-182-5p with low to moderate diagnostic ability (AUC = 0.692, 0.778, 0.687 and 0.745, respectively) were selected as candidate miRNAs after the three-stage study. The final diagnostic panel was consisted by miR-224-5p, miR-34b-3p and miR-182-5p with AUC = 0.855. No significance has been found between these four miRNAs and tumor location, Fuhrman Grade and AJCC clinical stages of RCC. Bioinformatic analysis suggested that the three-miRNAs panel may participate in tumorigenesis of RCC by targeting CORO1C. CONCLUSIONS: The three-miRNA panel in serum could serve as a non-invasive diagnostic biomarker of RCC.
PURPOSE:Renal cell carcinoma (RCC) accounts for about 120,000 death each year. Although surgery is a routine treatment, RCC could be fatal if not diagnosed at an early stage. This study aims to search for suitable serum biomarkers and construct a miRNA panel with high diagnostic sensitivity or specificity. METHODS: Totally 146 RCCpatients and 150 normal control were involved in this three-stage study. Serum expression levels of 30 miRNAs selected from literature were tested by reverse transcription quantitative PCR (RT-qPCR) in the screening stage, the testing stage, and the validation stage. The diagnostic efficiency of miRNAs was evaluated by receiver operating characteristic (ROC) curve and area under curve (AUC) analysis. A panel with the highest diagnostic efficiency was constructed by backward stepwise logistic regression analysis. Additionally, bioinformatics analysis was used to investigate potential biological functions and mechanisms of candidate miRNAs. RESULTS:MiR-224-5p, miR-34b-3p, miR-129-2-3p and miR-182-5p with low to moderate diagnostic ability (AUC = 0.692, 0.778, 0.687 and 0.745, respectively) were selected as candidate miRNAs after the three-stage study. The final diagnostic panel was consisted by miR-224-5p, miR-34b-3p and miR-182-5p with AUC = 0.855. No significance has been found between these four miRNAs and tumor location, Fuhrman Grade and AJCC clinical stages of RCC. Bioinformatic analysis suggested that the three-miRNAs panel may participate in tumorigenesis of RCC by targeting CORO1C. CONCLUSIONS: The three-miRNA panel in serum could serve as a non-invasive diagnostic biomarker of RCC.
Authors: Ramaprasad Srinivasan; Christopher J Ricketts; Carole Sourbier; W Marston Linehan Journal: Clin Cancer Res Date: 2015-01-01 Impact factor: 12.531
Authors: Jacques Ferlay; Hai-Rim Shin; Freddie Bray; David Forman; Colin Mathers; Donald Maxwell Parkin Journal: Int J Cancer Date: 2010-12-15 Impact factor: 7.396
Authors: W Marston Linehan; Laura S Schmidt; Daniel R Crooks; Darmood Wei; Ramaprasad Srinivasan; Martin Lang; Christopher J Ricketts Journal: Cancer Discov Date: 2019-05-14 Impact factor: 39.397
Authors: Bartlomiej E Krazinski; Jolanta Kiewisz; Agnieszka Sliwinska-Jewsiewicka; Anna E Kowalczyk; Jedrzej Grzegrzolka; Janusz Godlewski; Przemyslaw Kwiatkowski; Piotr Dziegiel; Zbigniew Kmiec Journal: Cancer Genomics Proteomics Date: 2019 May-Jun Impact factor: 4.069
Authors: Patrick S Mitchell; Rachael K Parkin; Evan M Kroh; Brian R Fritz; Stacia K Wyman; Era L Pogosova-Agadjanyan; Amelia Peterson; Jennifer Noteboom; Kathy C O'Briant; April Allen; Daniel W Lin; Nicole Urban; Charles W Drescher; Beatrice S Knudsen; Derek L Stirewalt; Robert Gentleman; Robert L Vessella; Peter S Nelson; Daniel B Martin; Muneesh Tewari Journal: Proc Natl Acad Sci U S A Date: 2008-07-28 Impact factor: 11.205
Authors: Calida S Neal; Michael Z Michael; Lesley H Rawlings; Mark B Van der Hoek; Jonathan M Gleadle Journal: BMC Med Date: 2010-10-21 Impact factor: 8.775
Authors: Chuan Shen; Rameen Beroukhim; Steven E Schumacher; Jing Zhou; Michelle Chang; Sabina Signoretti; William G Kaelin Journal: Cancer Discov Date: 2011-06-07 Impact factor: 39.397